Fighting Poor-Quality Medicines in Low- And Middle-Income Countries: The Importance of Advocacy and Pedagogy
MetadataShow full item record
AbstractThe globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly "involved" with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.
- The Belgian commitment to pharmaceutical quality: a model policy to improve quality assurance of medicines available through humanitarian and development programs.
- Authors: Ravinetto R, Roosen T, Dujardin C
- Issue date: 2018
- Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
- Authors: Olsson S, Pal SN, Stergachis A, Couper M
- Issue date: 2010 Aug 1
- Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.
- Authors: Van Assche K, Nebot Giralt A, Caudron JM, Schiavetti B, Pouget C, Tsoumanis A, Meessen B, Ravinetto R
- Issue date: 2018
- Fighting trafficking of falsified and substandard medicinal products in Russia.
- Authors: Fayzrakhmanov NF
- Issue date: 2015
- Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
- Authors: Ahonkhai V, Martins SF, Portet A, Lumpkin M, Hartman D
- Issue date: 2016